The sublingual vaccine MV140 is dominant over prophylactic antibiotics for the prevention of recurrent, uncomplicated urinary tract infections in adult women
A cost-utility analysis
DOI:
https://doi.org/10.5489/cuaj.9237Keywords:
recurrent urinary track infection, MV140 sublingual vaccine, cost-effectiveness analysisAbstract
Introduction: Recurrent, uncomplicated urinary tract infections (rUTIs) in women are associated with burdensome symptoms, high antibiotic use, and significant costs. The sublingual vaccine MV140 has demonstrated significant reduction in rUTI rates in Canada and Europe. This analysis examined the cost-effectiveness of MV140 as an alternative to prophylactic antibiotics (pAbs) for rUTI prevention in adult women in the Canadian healthcare setting.
Methods: A cost-utility model was developed to follow rUTI patients over 1.25 years through four health states: UTI-free survival, acute UTI, pyelonephritis, and death. A decision tree was used to model the acute UTI state, accounting for Ab resistance and choice of first-line Ab treatment, while Markov model transition probabilities were derived from a published direct comparison. Cost inputs included drug acquisition/administration, healthcare resource use, adverse events, and lost productivity, and were based on Canadian governmental resources. Utilities were derived from published literature. The base case was probabilistic (n=5000); multiple one-way sensitivity analyses were performed to assess model uncertainty.
Results: MV140 was associated with cost-savings (-$1442) and increased quality of life years (0.01) compared to pAbs, with an incremental cost-effectiveness ratio of -$229 088 in the base case (societal perspective). MV140 remained dominant over pAbs in most scenario analyses, with incremental costs ranging from -$256 207 to $875.
Conclusions: MV140 represents a consistently cost-effective alternative to pAbs in the Canadian healthcare system. When societal costs are considered, MV140 is consistently dominant over pAbs irrespective of variation in scenario inputs, demonstrating the considerable economic value of MV140 in this disease setting.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:
- Post the Article on any Web site
- Translate or authorize a translation of the Article
- Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
- Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.
The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.
You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.
The CUA also requires you to warrant the following:
- That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
- That all individuals who have made a substantive contribution to the article are acknowledged;
- That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
- That the Article does not libel or violate the privacy rights of any third party.
